Gynostemma pentaphyllum is a medicinal and edible plant belonging to the genus Gynostemma of the family Cucurbitaceae and has a long history of medicinal use. Its dried aerial parts are used medicinally. G. pentaphyllum is rich in various active components such as saponins, flavonoids and polysaccharides, and exhibits a wide range of pharmacological activities, such as lipid-regulating and hepatoprotective effects, adjuvant effects in cancer treatment, and amelioration of atherosclerosis.. This review systematically summarizes the research status and progress of marketed drugs containing G. pentaphyllum as the principal medicinal ingredient, with a focus on their pharmacological effects, basic research, clinical application and quality standards. It aims to provide theoretical support for the popularization, application and further development of G. pentaphyllum in clinical medicine, promote the development of the G. pentaphyllum industry towards standardization, modernization and internationalization, and support the inheritance and innovation of traditional Chinese medicine.
Key words
Gynostemma pentaphyllum (Thunb.) Makino
/
medicinal and edible plant
/
quality standards
/
secondary development
/
lipid regulation
/
hepatoprotection
BAO Beibei, ZHANG Peng, LI Yiting, TIAN Tao, XIE Yang.
Medicinal value of Gynostemma pentaphyllum and research progress in its marketed drugs[J].
Chinese Traditional and Herbal Drugs,
2026
, 57
(14)
: 5761
-5777
.
DOI: 10.7501/j.issn.0253-2670.2026.14.033
魏欣, 纪瑞锋, 徐娟, 等. 基于VOSviewer和CiteSpace知识图谱对绞股蓝研究热点与趋势分析[J]. 中草药, 2024, 55(9): 3064-3076. 李倩, 陈雨萌, 王煦焱, 等. 绞股蓝化学成分及其药理作用研究进展[J].辽宁中医药大学学报, 2025, 27(3): 104-112. 郑小江, 刘金龙, 田国政. 甜味绞股蓝不同部位多糖含量的研究[J]. 安徽农业科学, 2008, 36(30): 13223-13225. 葛锦蓉, 张子仪, 张兴明, 等. 绞股蓝资源分布、化学成分、检测方法及药理作用研究进展[J]. 中草药, 2025, 56(3): 1050-1063. 马文竹. 绞股蓝的历史沿革与应用价值[J]. 实用医技杂志, 2020, 27(11): 1544-1545. 彭震. 暗环境下绞股蓝的地上茎向根状茎转变发育研究[D]. 吉首: 吉首大学, 2024. 滕菲, 李祥溦, 李敏, 等. 绞股蓝地下部位总皂苷化学成分分析及降脂作用研究[J]. 中国中药杂志, 2022, 47(18): 5022-5031. 王航航, 韩慧发, 王吓长, 等. 绞股蓝皂苷糖基水解研究进展[J]. 中药材, 2023, 46(11): 2882-2889. 徐书杨, 杨紫晴, 滕菲, 等. 不同加工方式绞股蓝的抗炎活性比较研究[J]. 中国中药杂志, 2023, 48(19): 5235-5243. 张灵, 张倩茹, 刘代顺. 绞股蓝在治疗呼吸系统疾病中的应用[J]. 遵义医科大学学报, 2024, 47(7): 725-735. 彭亮, 李诒光, 陈杰, 等. 不同产地、不同品种绞股蓝总黄酮含量比较研究[J]. 亚太传统医药, 2015, 11(21): 33-35. Liu H, Li X M, Xie J B, et al. Gypenoside L and gypenoside LI inhibit proliferation in renal cell carcinoma via regulation of the MAPK and arachidonic acid metabolism pathways [J]. Front Pharmacol, 2022, 13: 820639. Geng Y, Yang J, Cheng X, et al. A bioactive gypenoside (GP-14) alleviates neuroinflammation and blood brain barrier (BBB) disruption by inhibiting the NF-κB signaling pathway in a mouse high-altitude cerebral edema (HACE) model [J]. Inter Immunopharmacol, 2022, 107: 108675. Cao L H, Zhao Y Y, Bai M, et al. Mechanistic studies of gypenosides in microglial state transition and its implications in depression-like behaviors: Role of TLR4/MyD88/NF-κB signaling [J]. Front Pharmacol, 2022, 13: 838261. 万俊阳, 宋囡, 张明香, 等. 绞股蓝皂苷调控铁死亡途径对ApoE-/-小鼠肝脏脂质沉积的影响及机制研究[J]. 世界科学技术—中医药现代化, 2022, 24(3): 1158-1165. Li H, Xi Y, Liu H, et al. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation [J]. Frontiers in Nutrition, 2022, 9: 914079. Han J, Gao W, Su D, et al. Gypenoside inhibits RANKL‐induced osteoclastogenesis by regulating NF‐κB, AKT, and MAPK signaling pathways [J]. J Cellular Biochem, 2018, 119(9): 7310-7318. Luo Y, Dong X, Lu S, et al. Gypenoside XVII alleviates early diabetic retinopathy by regulating Müller cell apoptosis and autophagy in db/db mice [J]. Eur J Pharmacol, 2021, 895: 173893. 张金金, 许哲远, 陈骞, 等. 绞股蓝多糖对抗疾病的药理学研究进展[J]. 中国妇幼保健, 2019, 34(7): 1684-1686. Shang X, Chao Y, Zhang Y, et al. Immunomodulatory and antioxidant effects of polysaccharides from Gynostemma pentaphyllum Makino in immunosuppressed mice [J]. Molecules, 2016, 21(8): 1085. Chi A, Tang L, Zhang J, et al. Chemical composition of three ingredients of polysaccharides from Gynostemma pentaphyllum and comparison of their antioxidant activity in skeletal muscle of exhaustive exercise mice [J]. Int J Sport Nutr Exerc Metab, 2012, 22: 479-485. 白熙, 刘新勇, 黎木兰, 等. 绞股蓝多糖对断乳雌性小鼠卵巢发育的影响[J]. 中国兽医科学, 2021, 51(4): 518-527. 唐非台, 刘可可, 杜倩笙, 等. 绞股蓝多糖对H2O2致体外成熟小鼠卵母细胞氧化损伤及凋亡的影响[J]. 中国兽医科学, 2024, 54(11): 1532-1539. 赵巍, 王建新, 阳长明. 中药制剂生产工艺变更研究管理历史、现状与思考[J]. 中草药, 2018, 49(12): 2729-2734. 熊皓舒, 田埂, 刘朋, 等. 中药生产过程质量控制关键技术研究进展[J]. 中草药, 2020, 51(16): 4331-4337. 匡艳辉, 张偲偲, 朱晶晶, 等. 不同工艺的绞股蓝总甙降血脂作用的对比研究[J]. 世界科学技术-中医药现代化, 2019, 21(5): 900-905. 蒋慧宣. 绞股蓝总皂苷原料制备工艺及质量标准研究[D]. 广州: 广州中医药大学, 2018. 张子龙, 李雯珊, 滕菲, 等. 绞股蓝总苷提取物及总苷片的质量标准研究[J]. 中国中药杂志, 2020, 45(24): 5976-5981. 蒋振忠, 唐学明, 李晓梅, 等. 复方绞股蓝胶囊质量标准的修订[J]. 云南中医学院学报, 2010, 33(4): 10-11. Ballard-Hernandez J, Sall J. Dyslipidemia update [J]. Nurs Clin North Am, 2023, 58(3): 295-308. Kwiterovich P O. Diagnosis and management of familial dyslipoproteinemias [J]. Curr Cardiol Rep, 2013, 15(6): 371. Chen H T, Mo P F, Xu G Q. Potential function of hepatic Niemann–Pick C1-like 1: Cholesterol homeostasis regulation of the canalicular lipid bilayer membrane [J]. Gastroenterol Rep: Oxf, 2025, 1310.1093: gastro. Al-Rashed F, Haddad D, Al Madhoun A, et al. ACSL1 is a key regulator of inflammatory and macrophage foaming induced by short-term palmitate exposure or acute high-fat feeding [J]. iScience, 2023, 26(7): 107145. Giordano S, Ielapi J, Salerno N, et al. Rationale for early administration of PCSK9 inhibitors in acute coronary syndrome [J]. Rev Cardiovascular Med, 2024, 25(10): 374. 王小刚, 赵娴, 李悦, 等. 高脂血症发病机制及治疗研究进展[J]. 辽宁中医药大学学报, 2020, 22(12): 196-200. Na S F, Fan Y J, Chen H L, et al. PPARα affects hepatic lipid homeostasis by perturbing necroptosis signals in the intestinal epithelium [J]. Acta Pharm Sin B, 2024, 14(11): 4858-4873. 王辉敏, 李冠文, 杨金梅, 等. 多不饱和脂肪酸降脂作用机制的研究进展[J]. 中国油脂, 2023, 48(5): 73-77. 彭卫华. 绞股蓝总苷分散片治疗高血脂患者的临床价值[J]. 中西医结合心血管病电子杂志, 2017, 5(16): 51. 沈竹阳. 基于脂噬-PCSK9-LDLR降解通路研究绞股蓝总皂苷降脂效应的机制[D]. 南京: 南京中医药大学, 2024. 邓萌玥, 杨长鑫, 冯宝文, 等. 绞股蓝总皂苷最佳治疗剂量筛选及其降脂保肝肾作用和机制研究[J]. 中国新药杂志, 2024, 33(5): 458-468. Xie P, Xie J B, Xiao M Y, et al. Liver lipidomics analysis reveals the anti-obesity and lipid-lowering effects of gypnosides from heat-processed Gynostemma pentaphyllum in high-fat diet fed mice [J]. Phytomedicine, 2023, 115: 154834. 吴柳松, 冯永怀, 钱民章. GPs抑制miRNA122表达及调节脂代谢酶活性降血脂作用研究[J]. 世界科学技术—中医药现代化, 2015, 17(8): 1679-1685. 曾迪, 周昌园, 龙健, 等. 基于脂质组学的绞股蓝总苷调血脂作用研究[J]. 中草药, 2023, 54(4): 1149-1156. Jia N, Lin X, Ma S, et al. Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in Gynostemma pentaphylla (Thunb.) Makino treated mice [J]. Nutrition Metabolism, 2018, 15(1): 86. Saleh A K, El-Masry T A, El-Kadem A H, et al. Exploring drug-induced liver injury: Comprehensive insights into mechanisms and management of hepatotoxic agents [J]. Future J Pharm Sci, 2025, 11(1): 38. He Y H, Jiang J L, Ou L L, et al. Impaired RelA signaling and lipid metabolism dysregulation in hepatocytes: Driving forces in the progression of metabolic dysfunction-associated steatotic liver disease [J]. Cell Death Discov, 2025, 11: 49. He B Y, Copps K D, Stöhr O, et al. Spatial regulation of glucose and lipid metabolism by hepatic insulin signaling [J]. Cell Metab, 2025, 37(7): 1568-1583. Horn P, Tacke F. Metabolic reprogramming in liver fibrosis [J]. Cell metabolism, 2024, 36(7): 1439-1455. 陈玮钰, 舒发明, 王涵, 等. 细胞色素P450家族在肝脏代谢相关疾病中的作用[J]. 临床肝胆病杂志, 2022, 38(9): 2182-2187. Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression [J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. 李旭鸿, 程卫东, 脱承德, 等. 宝干胶囊联合绞股蓝总苷片治疗大鼠高脂血症性脂肪肝的实验研究[J]. 时珍国医国药, 2009, 20(11): 2788-2789. 杨艳萍, 杜艺玫, 秦琳, 等. 绞股蓝总皂苷对高胆固醇血症模型小鼠主要尿蛋白基因表达的影响研究[J]. 中国药房, 2020, 31(15): 1809-1815. 李红山, 应豪, 胡爱荣, 等. HJJB复方对非酒精性脂肪性肝炎大鼠胰岛素信号转导环节的影响[J]. 中国中西医结合杂志, 2017, 37(9): 1109-1113. Deng Y D, Wang J M, Wu D, et al. Gypensapogenin A-liposomes efficiently ameliorates hepatocellular lipid accumulation via activation of FXR receptor [J]. Molecules, 2024, 29(17): 4080. Zhou M Y, Cao Y, Xie S C, et al. Gypenoside XLIX alleviates acute liver injury: Emphasis on NF-κB/PPAR-α/NLRP3 pathways [J]. Int Immunopharmacol, 2024, 131: 111872. Li H, Wang H H, Yang A P, et al. Gypenosides synergistically reduce the extracellular matrix of hepatic stellate cells and ameliorate hepatic fibrosis in mice [J]. Molecules, 2023, 28(14): 5448. Hu L L, Zhao X, He X, et al. Gynostemma pentaphyllum ameliorates CCl4-induced liver injury via PDK1/Bcl-2 pathway with comprehensive analysis of network pharmacology and transcriptomics [J]. Chin Med, 2024, 19(1): 70. 陈亮, 彭景华, 冯琴, 等. 绞股蓝总皂苷对四氯化碳诱导的大鼠肝纤维化肝细胞凋亡的影响[J]. 中华中医药杂志, 2015, 30(1): 211-215. 习晓丽, 叶美玲. 绞股蓝总苷胶囊对非酒精性脂肪性肝病病人糖脂代谢、氧化应激水平及肝纤维化指标的影响[J]. 安徽医药, 2022, 26(4): 824-828. Chen Y X, Zhou Y Y, Han F W, et al. A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis [J]. Theranostics, 2020, 10(16): 7193-7210. Qian S, Wei Z, Yang W, et al. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy [J]. Frontiers in Oncology, 2022, 12: 985363. Shen H, Liu B Q, Xu J J, et al. Circular RNAs: Characteristics, biogenesis, mechanisms and functions in liver cancer [J]. J Hematol Oncol, 2021, 14(1): 134. Zheng S Y, Chen Y, Zhu Z P, et al. Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: A review [J]. J Zhejiang Univ Science B, 2025, 26(8): 713-739. Dimari G, Hu Y, Frenzel A, et al. Mesenchymal-epithelial transition reduces proliferation but increases immune evasion in tumor spheroids [J]. iScience, 2025, 28(8): 113023. Wang F, Yi J F, Chen Y, et al. PRSS2 regulates EMT and metastasis via MMP-9 in gastric cancer [J]. Acta Histochem, 2023, 125(6): 152071. Tang D L, Kang R. NFE2L2 and ferroptosis resistance in cancer therapy [J]. Cancer Drug Resist, 2024, 7: 41. Wang Y, Yu G, Chen X. Mechanism of ferroptosis resistance in cancer cells [J]. Cancer Drug Resistance, 2024, 7: 47. Gao Y, Huang Y, Guo K, et al. Advances in research on the mechanism of tsRNA action in tumours[J]. Journal of Medical Genetics, 2025, 62(3): 152-159. Wang J J, Zhu N N, Su X M, et al. Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors [J]. Cancer Lett, 2024, 582: 216582. 高浩, 赵佼, 陈威言, 等. 绞股蓝总苷介导METTL3调控m6A甲基化对卵巢癌细胞糖酵解的影响[J]. 中国临床药理学杂志, 2024, 40(22): 3264-3269. 崔鹏, 朱敬轩, 赵佼, 等. 绞股蓝皂苷L通过miR-1291/ERRα/CPT1C调控卵巢癌细胞增殖代谢的分子机制[J]. 辽宁中医杂志, 2025, 52(9): 147-151. 邓芙蓉, 王翰林, 谢佩佩, 等. 绞股蓝皂苷对人胃癌细胞增殖和凋亡的影响及作用机制[J]. 中国药理学通报, 2023, 39(4): 646-652. 王柏山, 孙小扉, 杨莹, 等. circ-0002133/miR-182/ Bcl2L12轴影响细胞凋亡与肝癌发生发展及绞股蓝皂苷的干预作用[J]. 中华中医药学刊, 2025, 43(7): 35-40. 刘剑波, 毕小玲, 王世华, 等. 绞股蓝皂苷药理作用研究进展[J]. 中成药, 2024, 46(10): 3358-3363. Su C, Li N, Ren R R, et al. Progress in the medicinal value, bioactive compounds, and pharmacological activities of Gynostemma pentaphyllum [J]. Molecules, 2021, 26(20): 6249. 朱敬轩, 赵佼, 王群, 等. 基于mature-tRNA-Asp-GTC/ ATF3-LPCAT3介导的铁死亡途径探讨绞股蓝皂苷L抗卵巢癌的分子机制[J]. 中国实验方剂学杂志, 2025, 31(11): 107-117. 余素清, 刘京生, 韩彩芝, 等. 复方绞股蓝黄芪汤对提高消化系统癌患者外周血自然杀伤细胞活性实验研究[J]. 河北中医, 1996(1): 21-22. 王震, 武文妍, 周曾同. 基于预后分析的复方绞股蓝胶囊预防口腔白斑癌变的回顾性队列研究[J]. 上海中医药杂志, 2019, 53(9): 51-55. 尹祥敏, 于信民, 高中民, 等. 复方绞股蓝胶囊治疗中晚期胃癌的临床疗效观察[J]. 菏泽医学专科学校学报, 1999, 11(4): 1-3. Björkegren J L M, Lusis A J. Atherosclerosis: Recent developments [J]. Cell, 2022, 185(10): 1630-1645. Deng W Y, Zhou C L, Zeng M Y. Gypenoside XVII inhibits ox-LDL-induced macrophage inflammatory responses and promotes cholesterol efflux through activating the miR-182-5p/HDAC9 signaling pathway [J]. J Ethnopharmacol, 2024, 319: 117070. Alsalman Z M, Zhu Q, Hu J, et al. Roles of mitochondrial quality control in the pathogenesis of atherosclerosis [J]. Cardiovasc Innov Appl, 2025, 10(1): 970. Gao M, Heng X, Jin J, et al. Gypenoside XLIX ameliorate high-fat diet-induced atherosclerosis via regulating intestinal microbiota, alleviating inflammatory response and restraining oxidative stress in ApoE-/- mice [J]. Pharmaceuticals, 2022, 15(9): 1056. Bao Y L, Zhu L, Wang Y T, et al. Gualou-Xiebai herb pair and its active ingredients act against atherosclerosis by suppressing VSMC-derived foam cell formation via regulating P2RY12-mediated lipophagy [J]. Phytomedicine, 2024, 128: 155341. Luo H Y, Chen J B, Su C H, et al. Advances in the bioactivities of phytochemical saponins in the prevention and treatment of atherosclerosis [J]. Nutrients, 2022, 14(23): 4998. Chen W R, Yang J Q, Liu F, et al. Melatonin attenuates vascular calcification by activating autophagy via an AMPK/mTOR/ULK1 signaling pathway [J]. Exp Cell Res, 2020, 389(1): 111883. 宋囡, 陈宁, 曹慧敏, 等. 绞股蓝总苷调控生物节律相关蛋白对ApoE-/-小鼠动脉粥样硬化的影响[J]. 中华中医药学刊, 2021, 39(8): 248-251. 杨佳鑫, 马粉花, 张吉涛, 等. 绞股蓝总皂苷抑制大鼠动脉粥样硬化炎症反应并影响TLR4/MyD88/NF-κB信号通路表达[J]. 基因组学与应用生物学, 2022, 41(1): 193-202. 吴迪, 焦雪, 袁泽利, 等. 绞股蓝总皂苷抑制脂多糖诱导的血管内皮损伤[J]. 中国新药杂志, 2020, 29(3): 323-328. 首朝曦, 张吉涛, 吴宁, 等. 绞股蓝总皂苷通过PPAR-γ与Wnt途径影响大鼠动脉粥样硬化及部分有效成分预测[J]. 贵州医科大学学报, 2024, 49(7): 957-965. Song N, Jia L Q, Cao H M, et al. Gypenoside inhibits endothelial cell apoptosis in atherosclerosis by modulating mitochondria through PI3K/Akt/bad pathway [J]. BioMed Res Int, 2020, 2020: 2819658. 赵卓, 高浩, 杨莹, 等. 绞股蓝皂苷抑制Bcl2L12凋亡通路改善ApoE-/-动脉粥样硬化小鼠肝脏脂质沉积[J]. 中国中西医结合杂志, 2023, 43(10): 1221-1227. 曹慧敏, 宋囡, 贾连群, 等. 绞股蓝不同有效成分对ox-LDL诱导内皮细胞自噬效应的影响[J]. 中华中医药学刊, 2018, 36(5): 1166-1168. 张妮, 宋囡, 曹慧敏, 等. 绞股蓝总皂苷调节自噬小体对动脉粥样硬化的防治作用[J]. 天然产物研究与开发, 2017, 29(12): 2112-2116. 邢雁伟, 腾菲, 高永红, 等. 绞股蓝总甙片联合阿托伐他汀钙片治疗对冠心病合并高脂血症患者血脂以及炎症指标的影响[J]. 中西医结合心脑血管病杂志, 2013, 11(6): 655-657. 裴晓宁. 葛兰心宁软胶囊联合富马酸比索洛尔治疗冠心病心绞痛的临床研究[J]. 中华中医药学刊, 2020, 38(6): 169-172. 王阶, 许军, 温林军, 等. 葛兰心宁对冠心病心绞痛患者中医证候疗效及血管内皮功能的影响[J]. 中国医药学报, 2004, 19(10): 595-597. 王阶, 许军, 张丽娟, 等. 葛兰心宁软胶囊对冠心病心绞痛患者免疫炎症因子的影响[J]. 临床心血管病杂志, 2005, 21(3): 141-143. 高晓东, 彭雪梅, 张武宁, 等. 葛兰心宁软胶囊对老年女性急性冠脉综合征患者的疗效[J]. 中国老年学杂志, 2012, 32(23): 5241-5242. 洪波. 绞股蓝口服液治疗白细胞减少症39例观察[J]. 中国中医药信息杂志, 1998, 5(8): 58. 马百芳, 宋执敬, 曹兰芝. 绞股蓝总甙胶囊治疗寻常型银屑病120例[J]. 皮肤病与性病, 1995, 17(1): 20-22. 陈刚, 汪雄, 李莉. 口服绞股蓝总甙片减少正常人血小板表面α-颗粒膜蛋白[J]. 同济医科大学郧阳医学院学报, 1994(1): 9-10. 张淑慎, 康纪年. 人参皂甙片与绞股蓝总皂甙片治疗虚证各30例临床及血象的对比观察[J]. 重庆医科大学学报, 1996, 21(1): 63-64. 曹文杰, 杨一玖, 王巍力, 等. 基于临床综合评价的中成药临床精准定位多维整合方法的探索[J]. 中国中医基础医学杂志, 2025, 31(6): 974-978. 陈婵婵, 宋明爱, 燕浩, 等. 绞股蓝多糖通过LncRNA XIST/TGF-β1对糖尿病肾病间质纤维化的影响及机制[J]. 中国老年学杂志, 2025, 45(18): 4498-4504. 刘艳菊, 刘景超, 王永飞. 绞股蓝多糖对MFC胃癌荷瘤小鼠肿瘤生长抑制及免疫调节作用[J]. 中成药, 2019, 41(12): 2876-2881. 李景良, 娄振岭, 马丽萍, 等. 绞股蓝多糖口服液治疗失眠症62例临床分析[J]. 河南医科大学学报, 1996(3): 90-91. 张海力, 曹文杰, 王巍力, 等. 多维度多准则中成药综合评价技术指导原则解读: 评价指标体系的信效度检验[J]. 中国中医基础医学杂志, 2025, 31(6): 1093-1099. 胡思源, 马融, 李梅芳, 等. 多维度多准则儿童中成药临床综合评价指标框架的构建[J]. 中草药, 2024, 55(5): 1427-1435. 马融, 戎萍, 张喜莲. 儿童中成药的精准治疗[J]. 药物评价研究, 2022, 45(9): 1735-1738. 陈子佳, 乔萌, 雷超, 等. 上市后中成药说明书安全性信息修订证据体的构建: 以消渴安胶囊为例[J]. 中国实验方剂学杂志, 2024, 30(10): 217-224. 陈琳, 郭敬, 刘斌, 等. 中药改良型新药研发模式解析与实施策略[J]. 中国中医基础医学杂志, 2025, 31(8): 1353-1358. 李烨, 徐乐加, 郑丹微, 等. 五味子上市药品研究进展[J]. 中草药, 2025, 56(4): 1467-1476. 喻樊. 绞股蓝总皂苷脂质体的制备与表征[J]. 中草药, 2013, 44(18): 2526-2530. 郭娅丽, 文丽梅, 代武, 等. 松果菊苷自微乳化给药系统的制备及在体肠吸收特性研究[J]. 中草药, 2025, 56(18): 6569-6579. 钟婉华, 刘丹霞, 崔升淼. 绞股蓝总皂苷自微乳化给药系统的制备[J]. 药学研究, 2015, 34(11): 654-657. Dong X, Suo Y, Yu J, et al. Biomimetic nanoparticles simultaneously targeting modulation of lipid metabolism and phenotype of macrophages for programmed atherosclerosis management [J]. ACS Nano, 2025, 19(28): 25628-25644. Abdulwahab S, Suardi N, Ali Dheyab M, et al. Functional green nanoemulsions with biosurfactants: Synthesis, surface engineering and advanced food, cosmetic, agricultural and biomedical applications [J]. Adv Colloid Interface Sci, 2025, 346: 103685. 申进宝, 孙红武. 绞股蓝总皂苷纳米乳的制备及其抗衰老作用研究[J]. 中国药房, 2012, 23(39): 3654-3658. 马双成, 王莹. 我国中药质量控制模式及思路研究进展十年回顾[J/OL]. 中国药学杂志, 1-21[2026-01-31]. http://link.cnki.net-s.dres.hactcm.edu.cn/urlid/11.2162.R.20230104.2122.001. 邓哲, 荆文光, 刘安. 薄层色谱法在当前中药质量标准中的应用探讨[J]. 中国实验方剂学杂志, 2019, 25(7): 201-206. 于学海, 禹玉洪, 宋海龙, 等. 绞股蓝总苷分散片指纹图谱及3个成分的定量分析[J].中成药, 2014, 36(4): 758-762. 中华中医药学会《中药质量标志物研究技术指南》编写组. 中药质量标志物研究技术指南[J]. 中草药, 2025, 56(7): 2249-2252. 司原琦, 付雨, 刘洪宇. 我国保健食品剂型分析及优化研究[J/OL]. (2025-11-05) [2026-02-01]. http://doi.org/10.13995/j.cnki.11-1802/ts.044213. 蔡谨莲, 蒙登妮, 黄凯, 等. 药食同源物质: 健康益处、安全性及在食品领域的应用现状[J]. 食品与发酵工业, 2026, 52(12): 459-468.
PDF下载
全屏
57
15
关闭全屏
北京市海淀区学院南路86号
010-62199257（仅加盟咨询）
qkjq@cast.org.cn
